Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hairfollicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.
PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfollicle stem cells, but minoxidil and finasteride are still the main treatments.
DHT may inhibit hair growth by affecting mitochondrial function, leading to hairfollicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hairfollicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.
Hair loss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.